Enliven Therapeutics ELVN Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $20.69M-2.6% | $21.25M+16.6% | $18.23M-15.2% | $21.49M-13.7% | $24.9M+20.1% | ||
| $7.14M-45.3% | $13.04M+89.8% | $6.87M-3.1% | $7.09M+4.3% | $6.8M+10.1% | ||
| $27.82M-18.8% | $34.29M+36.6% | $25.1M-12.2% | $28.58M-9.8% | $31.69M+17.8% | ||
| $27.82M-18.8% | $34.29M+36.6% | $25.1M-12.2% | $28.58M-9.8% | $31.69M+17.8% | ||
| -$27.82M+18.8% | -$34.29M-36.6% | -$25.1M+12.2% | -$28.58M+9.8% | -$31.69M-17.8% | ||
| $4.2M-9.1% | $4.62M-6.7% | $4.95M+52.2% | $3.25M+1.7% | $3.2M-14.0% | ||
| $4.2M-9.1% | $4.62M-6.7% | $4.95M+52.3% | $3.25M+3.2% | $3.15M-15.3% | ||
| -$23.63M+20.4% | -$29.67M-47.2% | -$20.15M+20.5% | -$25.34M+11.2% | -$28.54M-23.1% | ||
| -$0.38+20.8% | -$0.48-50.0% | -$0.32+34.7% | -$0.49+14.0% | -$0.57-23.9% | ||
| -$0.38+20.8% | -$0.48-50.0% | -$0.32+34.7% | -$0.49+14.0% | -$0.57-23.9% | ||
| 62.8M+10.8% | 56.7M-8.7% | 62.1M+19.2% | 52.1M+4.1% | 50.1M+6.3% | ||
| 62.8M+10.8% | 56.7M-8.7% | 62.1M+19.2% | 52.1M+4.1% | 50.1M+6.3% | ||
| $4.2M-9.1% | $4.62M-6.7% | $4.95M+52.2% | $3.25M+1.7% | $3.2M-14.0% | ||
| -$24.34M+17.6% | -$29.55M-49.6% | -$19.75M+22.5% | -$25.5M+10.9% | -$28.62M-22.5% | ||
| -$716K-734% | $113K-71.6% | $398K+347% | -$161K-127% | -$71K+62.0% | ||
| $0— | $0— | $0+100% | -$2K+95.7% | -$47K— | ||
| -$27.82M+18.8% | -$34.29M-36.6% | -$25.1M+12.2% | -$28.58M+9.8% | -$31.69M-17.8% | ||
| -$27.81M+18.8% | -$34.24M-36.8% | -$25.03M+12.2% | -$28.5M+9.9% | -$31.62M-17.9% | ||
| -$27.81M+18.8% | -$34.24M-36.8% | -$25.03M+12.2% | -$28.5M+9.9% | -$31.62M-17.9% | ||
| -$27.82M+18.8% | -$34.29M-36.6% | -$25.1M+12.2% | -$28.58M+9.8% | -$31.69M-17.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Enliven Therapeutics profitable?
- Enliven Therapeutics is not currently profitable: it reported a net loss of $98.8M over the trailing twelve months.
- What is Enliven Therapeutics's earnings per share?
- Enliven Therapeutics's diluted EPS over the trailing twelve months is $-1.67.
- Where does Enliven Therapeutics's income statement data come from?
- Every line is extracted from Enliven Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.